Plasma Fractionation Market Projected to Reach US$ 65 Billion by 2032, With 7.3% CAGR | Fact.MR

The plasma fractionation market is projected to be valued US$ 32 billion in 2022. Moreover, growth is anticipated to pick up speed at a 7.3% CAGR over the assessment period of 2022-2032 and reach US$ 65 billion. The primary driver of the market's growth is the aging of the global population, which makes people more vulnerable to rare illnesses that call for the usage of blood derivatives.

Furthermore, it is anticipated that the growing global use of alpha-1-antitrypsin and immunoglobulins in a number of medical specialties would promote market growth. Another important element driving the growth of this market is the expansion of blood collection facilities worldwide. The primary factors anticipated to propel the global plasma fractionation market are the rise in innovation expenditure, the demand for plasma proteins, and the prevalence of rare diseases worldwide. The plasma fractionation industry has been making investments in the study and creation of innovative plasma protein therapeutics (such ceruloplasmin, IgA, and plasmin) for the benefit of patients.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭-
https://www.factmr.com/connectus/sample?flag=S&rep_id=4806

For example, Grifols announced in March 2016 that it would invest US$ 360 million to boost its production capacity for plasma-derived therapies. It is expected that the investment will improve the capacity to separate and isolate different types of proteins from plasma. Furthermore, more money spent on innovation leads to technological advancements in efficient and reasonably priced ways to separate proteins from plasma, which in turn boosts the plasma fractionation market. However, a number of factors, including growing market penetration of recombinant factors, stringent regulations, and concerns over reimbursement, are severely constraining the industry.

𝐊𝐞𝐲 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐏𝐥𝐚𝐬𝐦𝐚 𝐅𝐫𝐚𝐜𝐭𝐢𝐨𝐧𝐚𝐭𝐢𝐨𝐧 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐒𝐮𝐫𝐯𝐞𝐲

By Product :
Albumin
Immunoglobulins
Intravenous Immunoglobulins
Subcutaneous Immunoglobulins
Others
Coagulation Factors
Factor VIII
Factor IX
Von Willebrand Factor
Prothrombin Complex Concentrates
Fibrinogen Concentrates
Others
Protease Inhibitors
Others

By Method :

Centrifugation
Depth Filtration
Chromatography
Others

By Application :

Neurology
Hematology
Oncology
Immunology
Pulmonology
Others

By End User :

Hospitals & Clinics
Clinical Research
Others
By Region :
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 - https://www.factmr.com/connectus/sample?flag=RC&rep_id=4806

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐮𝐝𝐲

MR reports that from 2017 to 2022, the plasma fractionation market had a compound annual growth rate (CAGR) of 6%.
The market for plasma fractionation is anticipated to be valued US$ 32 billion in FY 2022.
Hospitals & clinics is anticipated to lead the market by end-user, with a 6.5% value CAGR.
According to GVR's forecasts, the UK market for plasma fractionation is expected to grow at a compound annual growth rate of 6.7%.
China's plasma fractionation market is anticipated to grow at a compound annual growth rate of 6.9%.

"Growing R&D initiatives, blood donation awareness programs, and corporate investments are anticipated to provide up profitable commercial opportunities for industry players in the global market," comments an analyst at Fact.MR

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

Leading companies in the plasma fractionation market are capitalizing on the constantly rising demand for plasma fractionation across a range of applications. The following are some notable market developments:

Terumo Blood and Cell Technologies opened its newest production facility in Douglas County, Colorado, in May 2022. The company's objectives of enhancing healthcare and expanding its customer base are aligned with the $250 million investment in a state-of-the-art production facility. The 170,000 square foot plant will produce single-use collection sets for the recently FDA-approved Rika Plasma Donation System (Rika) in order to provide clients with source plasma collections.
CSL Behring added new facilities at its manufacturing facility in Broadmeadows, Victoria, in May 2022, in accordance with the National Fractionation Agreement between the National Blood Authority and CSL Behring. The purpose of the new facilities was to increase processing capacity for Australia's expanding annual domestic plasma collections.

𝐏𝐫𝐨𝐦𝐢𝐧𝐞𝐧𝐭 𝐏𝐥𝐚𝐬𝐦𝐚 𝐅𝐫𝐚𝐜𝐭𝐢𝐨𝐧𝐚𝐭𝐢𝐨𝐧 𝐒𝐞𝐫𝐯𝐢𝐜𝐞 𝐏𝐥𝐚𝐲𝐞𝐫𝐬

Grifols S.A.
CSL Limited
Takeda Pharmaceutical Company Limited
Octapharma AG
Kedrion S.p.A
LFB S.A.
Biotest AG
Sanquin
Bio Products Laboratory Ltd.
Intas Pharmaceuticals Ltd

𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞

Fact.MR, in its new offering, presents an unbiased analysis of the global Plasma Fractionation market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of product (albumin, immunoglobulins, coagulation factors, protease inhibitors and others), method (centrifugation, depth filtration, chromatography and others), application (neurology, hematology, oncology, immunology, pulmonology and others), and end user (hospitals & clinics, clinical research and others) across five major regions (North America, Europe, Asia Pacific, Latin America and Middle East & Africa).

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.